Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 23 results.
User Information
Export Records
  1. 1.   A novel patient-derived orthotopic xenograft (PDOX) mouse model of highly-aggressive liver metastasis for identification of candidate effective drug-combinations
  2. Zhang, Zhiying; Hu, Kaiwen; Miyake, Kentaro; Kiyuna, Tasuku; Oshiro, Hiromichi; Wangsiricharoen, Sintawat; Kawaguchi, Kei; Higuchi, Takashi; Razmjooei, Sahar; Miyake, Masuyo; Chawla, Sant P; Singh,Shree Ram; Hoffman, Robert M
  3. Scientific reports. 2020, Nov 18; 10(1): 20105.
  1. 2.   Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin
  2. Day, C. P.; Carter, J.; Bonomi, C.; Hollingshead, M.; Merlino, G.
  3. International Journal of Cancer. 2012, Jan; 130(1): 190-199.
  1. 3.   Characterization, Mapping, and Distribution of the Two XMRV Parental Proviruses
  2. Cingoz, O.; Paprotka, T.; Delviks-Frankenberry, K. A.; Wildt, S.; Hu, W. S.; Pathak, V. K.; Coffin, J. M.
  3. Journal of Virology. 2012, Jan; 86(1): 328-338.
  1. 4.   Real-time PCR-based assay to quantify the relative amount of human and mouse tissue present in tumor xenografts
  2. Alcoser, S. Y.; Kimmel, D. J.; Borgel, S. D.; Carter, J. P.; Dougherty, K. M.; Hollingshead, M. G.
  3. BMC Biotechnology. 2011, Dec; 11
  1. 5.   Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization
  2. Fitzgerald, D. P.; Palmieri, D.; Hua, E.; Hargrave, E.; Herring, J. M.; Qian, Y. Z.; Vega-Valle, E.; Weil, R. J.; Stark, A. M.; Vortmeyer, A. O.; Steeg, P. S.
  3. Clinical & Experimental Metastasis. 2008 25(7): 799-810.
  1. 6.   Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models
  2. Varticovski, L.; Hollingshead, M. G.; Robles, A. I.; Wu, X. L.; Cherry, J.; Munroe, D. J.; Lukes, L.; Anver, M. R.; Carter, J. P.; Borgel, S. D.; Stotler, H.; Bonomi, C. A.; Nunez, N. P.; Hursting, S. D.; Qiao, W. H.; Deng, C. X. X.; Green, J. E.; Hunter, K. W.; Merlino, G.; Steeg, P. S.; Wakefield, L. M.; Barrett, J. C.
  3. Clinical Cancer Research. 2007, Apr; 13(7): 2168-2177.
  1. 7.   A new synthetic agent with potent but selective cytotoxic activity against cancer
  2. Cholody, W. M.; Kosakowska-Cholody, T.; Hollingshead, M. G.; Hariprakasha, H. K.; Michejda, C. J.
  3. Journal of Medicinal Chemistry. 2005, JUN 30; 48(13): 4474-4481.
  1. 8.   Formylpeptide receptor FPR and the rapid growth of malignant human gliomas
  2. Zhou, Y.; Bian, X. W.; Le, Y. Y.; Gong, W. H.; Hu, J. Y.; Zhang, X.; Wang, L. H.; Iribarren, P.; Salcedo, R.; Howard, O. M. Z.; Farrar, W.; Wang, J. M.
  3. Journal of the National Cancer Institute. 2005, JUN 1; 97(11): 823-835.
  1. 9.   Transduction of the gene coding for a human G-protein coupled receptor FPRL1 in mouse tumor cells increases host anti-tumor immunity
  2. Hu, J. Y.; Li, G. C.; Tong, Y. Q.; Li, Y. H.; Zhou, G. H.; He, X. J.; Xie, P. L.; Wang, J. M.; Sun, Q. B.
  3. International Immunopharmacology. 2005, JUN; 5(6): 971-980.
  1. 10.   Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer
  2. Palmieri, D.; Halverson, D. O.; Ouatas, T.; Horak, C. E.; Salerno, M.; Johnson, J.; Figg, W. D.; Hollingshead, M.; Hursting, S.; Berrigan, D.; Steinberg, S. M.; Merino, M. J.; Steeg, P. S.
  3. Journal of the National Cancer Institute. 2005, MAY 4; 97(9): 632-642.
  1. 11.   NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts
  2. Papadopoulou, M. V.; Bloomer, W. D.; Hollingshead, M. G.
  3. Anticancer Research. 2005, MAY-JUN; 25(3B): 1865-1869.
  1. 12.   Inhibition of melanoma growth and metastasis by ATF2-derived peptides
  2. Bhoumik, A.; Gangi, L.; Ronai, Z.
  3. Cancer Research. 2004, NOV 15; 64(22): 8222-8230.
  1. 13.   The experimental antitumor agents Phortress and Doxorubicin are equiactive against human-derived breast carcinoma xenograft models
  2. Fichtner, I.; Monks, A.; Hose, C.; Stevens, M. F. G.; Bradshaw, T. D.
  3. Breast Cancer Research and Treatment. 2004, SEP; 87(1): 97-107.
  1. 14.   Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor
  2. Wang, L. H.; Yang, X. Y.; Zhang, X. H.; Mihalic, K.; Fan, Y. X.; Xiao, W. H.; Howard, O. M. Z.; Appella, E.; Maynard, A. T.; Farrar, W. L.
  3. Nature Medicine. 2004 10(1): 40-47.
  1. 15.   O-6-benzylguanine-mediated enhancement of chemotherapy
  2. Friedman, H. S.; Keir, S.; Pegg, A. E.; Houghton, P. J.; Colvin, O. M.; Moschel, R. C.; Bigner, D. D.; Dolan, M. E.
  3. Molecular Cancer Therapeutics. 2002 1(11): 943-948.
  1. 16.   Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests
  2. Mi, Q. W.; Lantvit, D.; Reyes-Lim, E.; Chai, H. Y.; Zhao, W. M.; Lee, I. S.; Peraza-Sanchez, S.; Ngassapa, O.; Kardono, L. B. S.; Riswan, S.; Hollingshead, M. G.; Mayo, J. G.; Farnsworth, N. R.; Cordell, G. A.; Kinghorn, A. D.; Pezzuto, J. M.
  3. Journal of Natural Products. 2002 65(6): 842-850.
  1. 17.   Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2
  2. Kershaw, M. H.; Wang, G.; Westwood, J. A.; Pachynski, R. K.; Tiffany, H. L.; Marincola, F. M.; Wang, E.; Young, H. A.; Murphy, P. M.; Hwu, P.
  3. Human Gene Therapy. 2002 13(16): 1971-1980.
  1. 18.   Induction of transplantable mouse renal cell cancers by streptozotocin: In vivo growth, metastases, and angiogenic phenotype
  2. Gruys, M. E.; Back, T. C.; Subleski, J.; Wiltrout, T. A.; Lee, J. K.; Schmidt, L.; Watanabe, M.; Stanyon, R.; Ward, J. M.; Wigginton, J. M.; Wiltrout, R. H.
  3. Cancer Research. 2001 61(16): 6255-6263.
  1. 19.   Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-anticancer drug screen: Correlation with sensitivity to microtubule active agents
  2. Nicoletti, M. I.; Valoti, G.; Giannakakou, P.; Zhan, Z. R.; Kim, J. H.; Lucchini, V.; Landoni, F.; Mayo, J. G.; Giavazzi, R.; Fojo, T.
  3. Clinical Cancer Research. 2001 7(9): 2912-2922.
  1. 20.   A new human prostate carcinoma cell line, 22R upsilon 1
  2. Sramkoski, R. M.; Pretlow, T. G.; Giaconia, J. M.; Pretlow, T. P.; Schwartz, S.; Sy, M. S.; Marengo, S. R.; Rhim, J. S.; Zhang, D. S.; Jacobberger, J. W.
  3. In Vitro Cellular & Developmental Biology.Animal. 1999 35(7): 403-409.
  1. 21.   Cadmium-induced inhibition of the growth and metastasis of human lung carcinoma xenografts: role of apoptosis
  2. Waalkes, M. P.; Diwan, B. A.
  3. Carcinogenesis. 1999 20(1): 65-70.
  1. 22.   Identification of Compounds With Preferential Inhibitory Activity Against Low-Nm23-Expressing Human Breast Carcinoma and Melanoma Cell Lines
  2. Freije, J. M. P.; Lawrence, J. A.; Hollingshead, M. G.; Delarosa, A.; Narayanan, V.; Grever, M.; Sausville, E. A.; Paull, K.; Steeg, P. S.
  3. Nature Medicine. 1997 3(4): 395-401.
  1. 23.   Calcium Signaling in Prostate Cancer Cells - Evidence For Multiple Receptors and Enhanced Sensitivity to Bombesin/Grp
  2. Wasilenko, W. J.; Cooper, J.; Palad, A. J.; Somers, K. D.; Blackmore, P. F.; Rhim, J. S.; Wright, G. L.; Schellhammer, P. F.
  3. Prostate. 1997 30(3): 167-173.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel